Mutual Funds Sahi Hai!
To avail the service, you will be redirected to loans.geojitcredits.com
Solara Active Pharma Sciences Ltd fell 4.17% today to trade at Rs 645. The BSE Healthcare index is down 1.85% to quote at 43175.04. The index is down 2.04 % over last one month. Among the other constituents of the index, Strides Pharma Science Ltd decreased 4.17% and Gland Pharma Ltd lost 3.84% on the day. The BSE Healthcare index went down 2.16 % over last one year compared to the 5.64% fall in benchmark SENSEX.
Solara Active Pharma Sciences Ltd has added 6.23% over last one month compared to 2.04% fall in BSE Healthcare index and 0.25% rise in the SENSEX. On the BSE, 8051 shares were traded in the counter so far compared with average daily volumes of 34893 shares in the past one month. The stock hit a record high of Rs 885.95 on 02 Dec 2024. The stock hit a 52-week low of Rs 441.1 on 04 Mar 2025.
Gland Pharma Ltd rose for a third straight session today. The stock is quoting at Rs 1915.3, up 1.55% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is down around 0.43% on the day, quoting at 24628.25. The Sensex is at 80338.6, down 0.47%. Gland Pharma Ltd has dropped around 2.16% in last one month.
Meanwhile, Nifty Pharma index of which Gland Pharma Ltd is a constituent, has dropped around 1.55% in last one month and is currently quoting at 21915.4, down 0.26% on the day. The volume in the stock stood at 1.1 lakh shares today, compared to the daily average of 2.57 lakh shares in last one month.
The PE of the stock is 27.37 based on TTM earnings ending June 25.
The Product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection 40 Units per 100 mL (0.4 Units per mL) and 20 Units per 100 mL (0.2 Units per mL) of PH Health Limited (PH Health).
This Product is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
According to IQVIA, the product had US sales of approximately USD 45 million for the twelve months ending June 2025.
The product is bioequivalent and therapeutically equivalent to the reference listed drug (RLD), VASOSTRICT Injection (0.4 Units/mL) and (0.2 Units/mL) of PH Health.
This product is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.
According to IQVIA, the product recorded U.S. sales of approximately USD 45 million for the twelve months ending June 2025.
Gland Pharma is one of the largest and fastest-growing injectable-focused companies, with a global footprint across 60 countries, including the United States, Europe, Canada, Australia, India, and other markets. It has a wide range of injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, oncology, and ophthalmic solutions. The company also pioneered Heparin technology in India.
The company’s consolidated net profit surged 49.88% to Rs 215.48 crore in Q1 FY26 as against Rs 143.76 crore posted in Q1 FY25. Revenue from operations increased by 7.41% YoY to Rs 1,505.62 crore for the quarter ended 30 June 2025.
The counter shed 0.05% to Rs 1,941 on the BSE.